On April 6, 2026, the U.S. molecule patent for dapagliflozin (Farxiga, AstraZeneca) expired, and the FDA granted final approval to 15 ANDA filers for generic dapagliflozin tablets in 5 mg and 10 mg strengths. First commercial marketing by first-to-file applicants began the same day, triggering shared 180-day exclusivity under Hatch-Waxman Paragraph IV. The entry of generic dapagliflozin marks one of the largest simultaneous generic launches in the SGLT2 inhibitor class and is expected to reshape formulary positioning for diabetes, heart failure, and chronic kidney disease indications.
This guide is for market-access professionals, payer strategists, formulary managers, and pharmacy teams who need to understand the generic dapagliflozin approval landscape, therapeutic equivalence ratings, Orange Book patent and exclusivity status, formulary switching implications, and what to monitor as competition expands.
Short answer
| Parameter | Detail |
|---|---|
| Brand name | Farxiga |
| Generic name | dapagliflozin |
| Brand manufacturer | AstraZeneca |
| NDA number | 202293 |
| Molecule patent expiration | April 6, 2026 |
| First ANDA approval date | April 6, 2026 |
| Number of ANDA filers (final approval) | 15+ (Inevntia, Sandoz, Micro Labs, Aurobindo, Biocon, MSN, Ajanta, Macleods, Aizant, Lupin, Cipla, Teva, and others) |
| Dosage forms/strengths approved | Tablets, 5 mg and 10 mg |
| Authorized generic | Yes (Prasco, A-S Medication Solutions, and others marketed AG before patent expiry) |
| Orange Book therapeutic equivalence | AB-rated (therapeutically equivalent to Farxiga) |
| 180-day exclusivity | Shared among first-to-file Paragraph IV filers |
| Secondary patents remaining | Formulation and method-of-use patents extend to 2029–2030 |
| Remaining combination products | Qtern (dapagliflozin/saxagliptin) — generic entry projected December 2029; Xigduo XR (dapagliflozin/metformin ER) — pending |
What happened: patent and ANDA timeline
Farxiga was originally approved by the FDA on January 8, 2014, for type 2 diabetes. Its indications expanded over subsequent years to include heart failure with reduced ejection fraction (HFrEF), heart failure (broader), and chronic kidney disease (CKD). The molecule patent (U.S. Patent No. covering the dapagliflozin compound) expired on April 6, 2026, opening the door for ANDA applicants with Paragraph IV certifications.
Key dates
| Date | Event |
|---|---|
| January 8, 2014 | Farxiga (dapagliflozin) NDA 202293 approved for T2D |
| 2015–2020 | Label expansions: heart failure, CKD indications |
| January 8, 2018 | Earliest Paragraph IV ANDA submissions (20+ ANDAs recorded) |
| April 6, 2026 | Molecule patent expired; FDA grants final approval to 15 ANDA filers |
| April 6, 2026 | First commercial marketing begins; shared 180-day exclusivity triggered |
| May 26, 2030 | Expiration of last qualifying Paragraph IV patent (per FDA records) |
ANDA filers approved April 6, 2026
According to FDA Paragraph IV certification records and published generic approval data, the following companies received final approval for dapagliflozin tablets 5 mg and 10 mg:
- Inevntia (ANDA A211156)
- Sandoz (ANDA A211312)
- Micro Labs (ANDA A211467)
- Aurobindo Pharma (ANDA A211468)
- Biocon Pharma (ANDA A211470)
- MSN Laboratories (ANDA A211478)
- Ajanta Pharma (ANDA A211482)
- Macleods Pharma (ANDA A211506)
- Aizant Drug Research Solutions (ANDA A211523)
- Lupin (ANDA A211531)
- Cipla (ANDA A211535)
- Teva Pharmaceuticals
- Additional filers with shared 180-day exclusivity
All received AB therapeutic equivalence ratings, meaning pharmacists can substitute generic dapagliflozin for Farxiga at the counter in states that permit generic substitution, unless the prescriber specifies "dispense as written."
Therapeutic equivalence and Orange Book status
The FDA's Orange Book lists generic dapagliflozin as AB-rated, indicating that the ANDA products are therapeutically equivalent to the reference listed drug (RLD) Farxiga. AB-rated products are considered to have the same active ingredient, dosage form, strength, route of administration, and bioequivalence as the RLD.
What AB rating means for substitution
| Aspect | Implication |
|---|---|
| Pharmacy-level substitution | Permitted in most states without prescriber intervention |
| State substitution laws | Check individual state boards; some states require patient notification |
| "Dispense as written" (DAW) | Prescriber can override substitution if clinically justified |
| Formulary tier impact | Generic dapagliflozin expected to move to Tier 1 or Tier 2 on most formularies |
| Multi-source designation | With 15+ generic suppliers, dapagliflozin qualifies as a multi-source drug with robust supply |
Payer and formulary implications
Immediate formulary impact
The simultaneous entry of 15+ generic manufacturers creates significant pricing pressure and formulary repositioning opportunities:
Tier movement: Generic dapagliflozin is expected to move to the lowest copay tier (Tier 1 or generic tier) on most Medicare Part D and commercial formularies within 1–2 plan years. Plans that previously required prior authorization for Farxiga may remove PA requirements for the generic.
IRA negotiated price context: Dapagliflozin was among the first 10 drugs selected for Medicare drug price negotiation under the Inflation Reduction Act, with a negotiated Maximum Fair Price (MFP) of $178.50 per 30-day supply effective January 1, 2026. Generic entry may further reduce net cost below this negotiated price.
PBM formulary updates: CVS Caremark, Express Scripts, and OptumRx typically update formularies within 6–12 months of multi-source generic entry. Expect generic dapagliflozin to receive preferred generic status, with Farxiga potentially moved to non-preferred brand or removed from formulary.
Step therapy changes: Plans that previously required metformin failure before SGLT2 inhibitor coverage may relax or remove step therapy for generic dapagliflozin, given its lower cost and established cardiovascular and renal benefit.
Medicare Part D
| Parameter | Detail |
|---|---|
| IRA Maximum Fair Price (2026) | $178.50 per 30-day supply |
| Generic pricing trajectory | Expected 39%+ discount from brand WAC in year 1; up to 80% discount with 4+ competitors |
| Coverage phase | Part D pharmacy benefit; subject to annual deductible, then copay/coinsurance |
| $2,000 out-of-pocket cap | Applies; generic dapagliflozin contributes less toward the cap than brand Farxiga |
Commercial insurance
- Most commercial plans will add generic dapagliflozin to their generic tier with $0–$10 copay
- Prior authorization requirements may be relaxed or eliminated for the generic
- Brand Farxiga may require step edit through generic dapagliflozin before approval
- AstraZeneca's patient assistance and copay programs for Farxiga may shift in response to generic availability
Medicaid
- State Medicaid programs typically mandate generic substitution for multi-source drugs
- Generic dapagliflozin will be priced at Federal Upper Limit (FUL) or state MAC rates
- Supplemental rebate negotiations for Farxiga may become less relevant as generic market share grows
Combination products still under patent
While generic dapagliflozin monotherapy is now available, several combination products remain patent-protected:
| Product | Components | NDA | Generic entry projection |
|---|---|---|---|
| Qtern | dapagliflozin / saxagliptin | 209091 | ~December 2029 (per FDA Paragraph IV data) |
| Xigduo XR | dapagliflozin / metformin ER | 205649 | Pending ANDA resolution |
| Qternmet XR | dapagliflozin / saxagliptin / metformin ER | — | Later than Qtern |
Access teams should note that patients on combination products (Qtern, Xigduo XR) will not be able to switch to a single generic dapagliflozin tablet without also addressing the second or third active ingredient. Prescriber action is required to separate the combination into individual components.
SGLT2 inhibitor class landscape after generic entry
Generic dapagliflozin changes the SGLT2 competitive dynamic:
| Drug | Generic status | Pricing trajectory |
|---|---|---|
| Farxiga (dapagliflozin) | Generic available April 2026 | Rapidly declining |
| Jardiance (empagliflozin) | Drug substance patent expires 2027; method-of-use patents extend to Dec 2034; 14 ANDAs eligible | Brand pricing maintained through patent thicket |
| Invokana (canagliflozin) | Generic available (patent expired) | Already generic-tier |
| Brenzavvy (bexagliflozin) | Relatively new; no generic near-term | Brand pricing |
The key competitive shift: dapagliflozin becomes the first generic SGLT2 inhibitor with a full label including heart failure and CKD indications, while empagliflozin (Jardiance) remains brand-only until the early 2030s. Payers may preferentially position generic dapagliflozin over Jardiance using step therapy or preferred formulary tiering, especially given the class effect evidence for cardiovascular and renal outcomes across SGLT2 inhibitors.
What access teams should do now
Verify Orange Book equivalence: Confirm AB-rating with your wholesaler and pharmacy benefit manager. All 15+ approved ANDAs carry AB ratings for both 5 mg and 10 mg strengths.
Audit current Farxiga utilization: Identify patients currently on brand Farxiga who can be switched to generic dapagliflozin. Work with prescribers to update prescriptions.
Update formulary position: If managing a formulary, evaluate whether generic dapagliflozin should be Tier 1 preferred generic, and whether Farxiga should require generic-first step therapy.
Review combination product patients: Patients on Qtern or Xigduo XR cannot automatically receive generic dapagliflozin — the combination must be addressed holistically.
Monitor IRA negotiated price vs. generic net cost: The $178.50/month MFP for dapagliflozin under Medicare may be above or below the emerging generic net cost depending on rebate dynamics. Track actual acquisition cost (AAC) and wholesale acquisition cost (WAC) as generic competition stabilizes.
Educate providers on therapeutic equivalence: Reinforce that AB-rated generic dapagliflozin is bioequivalent to Farxiga for all approved indications, including heart failure and CKD.
What to monitor next
Generic pricing data: Monitor NADAC (National Average Drug Acquisition Cost) and WAC trends for dapagliflozin over the next 6–12 months as the 15+ manufacturers compete.
PBM formulary updates: Watch CVS Caremark, Express Scripts, and OptumRx formulary changes in Q3–Q4 2026. Expect generic dapagliflozin on preferred tiers.
Secondary patent litigation: AstraZeneca holds formulation and method-of-use patents extending to 2029–2030. Monitor for any litigation that could delay generic combinations (Qtern, Xigduo XR).
Jardiance market share impact: As generic dapagliflozin prices drop, payers may shift Jardiance (empagliflozin) patients to dapagliflozin. Watch for step therapy edits targeting empagliflozin.
Supply chain stability: With 15+ suppliers, dapagliflozin generic supply should be robust. Monitor FDA drug shortage database for any manufacturing issues.
Sources
- FDA. Paragraph IV Patent Certifications (May 11, 2026 update). fda.gov/media/166048/download
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. accessdata.fda.gov/scripts/cder/ob
- FDA. Drugs@FDA: Farxiga NDA 202293. accessdata.fda.gov/scripts/cder/daf
- CMS. Selected Drugs and Negotiated Prices — Medicare Drug Price Negotiation Program. cms.gov/initiatives/medicare-prescription-drug-affordability
- Rode S, Deshpande P, Dantkale D. Dapagliflozin Tablet Patents and Generic Launch: Recent Developments. Int J Pharm Sci. 2026;4(5):4818–4821. ijpsjournal.com
- Aurobindo Pharma. USFDA Final Approval for Dapagliflozin Tablets (press release, April 2026). aurobindo.com
- AHA Journals. Cost-Effectiveness of Sodium-Glucose Co-Transporter-2 Inhibitors (negotiated price data, 2026). ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012989
- DrugPatentWatch. Farxiga (dapagliflozin) patent and generic entry data. drugpatentwatch.com
